THTX - Theratechnologies Inc.

1.55
-0.090   -5.806%

Share volume: 727,147
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$1.64
-0.09
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
10%
Profitability 0%
Dept financing 27%
Liquidity 75%
Performance 0%
Company vs Stock growth
vs
16.111 M 16.400 M
289.000 K 1.79%
N/A
+ Add row to compare
Performance
5 Days
4.73%
1 Month
3.33%
3 Months
-17.11%
6 Months
27.05%
1 Year
0.65%
2 Year
-53.87%
Key data
Stock price
$1.55
P/E Ratio 
0.00
DAY RANGE
$1.52 - $1.74
EPS 
-$0.16
52 WEEK RANGE
$1.08 - $2.18
52 WEEK CHANGE
$4.73
MARKET CAP 
58.855 M
YIELD 
N/A
SHARES OUTSTANDING 
45.981 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-09-2025
BETA 
0.54
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$514,344
AVERAGE 30 VOLUME 
$2,803,037
Company detail
CEO: Paul Lévesque
Region: US
Website: theratech.com
Employees: 140
IPO year: 2009
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Theratechnologies Inc. focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV.

Recent news
loading